Immune checkpoint blockade (ICB) therapies that target cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have resulted in durable antitumor responses in a subset of cancer patients. This evidence concerns the gene CTLA4 and cancer.